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 INTRODUCTION 
 The most recent meeting was held in Yaoundé, Cameroon, 
March 12–15, 2009, coincident with the 1st meeting of the 
Cameroonian Society of Human Genetics. The scientific pro-
gram comprised several scientific sessions covering research 
topics relevant to human genetic research in Africa as well as 
public health and training. The three keynote speakers were 
Dr. Sir Richard Roberts, 1993 Nobel Laureate in Medicine and 
Chief Scientic Officer of New England Biolabs (NEB), Dr. Eric 
Green, Head of the United States National Human Genome 
Institute (NHGRI), and Prof. Michael Hayden, Director of 
the Medical Genetics Department at the University of British 
Columbia. Dr. Roberts opened the conference with a talk 
describing his work from the 1970s at Cold Spring Harbour 
Laboratories, first on restriction endonucleases and then, on 
adenovirus-2 late mRNA mapping that led to the discovery of 
RNA splicing. He also gave a brief description on how NEB 
operates and its commitment to be a community integrated and 
eco-friendly facility. Dr. Green described the research objec-
tives and capabilities of NHGRI, and Prof. Hayden presented 
scenarios of how pharmacogenetics research can be and has 
been performed in settings relevant to sub-Saharan Africa. 
 The scientific sessions comprised the following topics and 
some highlights as described below. 
 HUMAN ORIGINS AND GENETIC DIVERSITY 
 This session covered topics that included the description of 
patterns of genetic variation among indigenous South Africans, 
using high-density genetic data and how such studies can aid 
in understanding both anthropological diversity within Africa 
as well as the role of genetics in response to therapeutics, a 
significantly understudied topic in Africa (Prof. Raj Ramesar, 
University of Cape Town , Cape Town, South Africa). This 
talk made a strong case for understanding population struc-
ture to analyze complex diseases. Data were presented on five 
indigenous populations (Herero, San, Sotho/Tswana, Xhosa, 
and Zulu) that were genotyped using the Affymetrix SNP 6 
microarray technology. This chip assays 1.8 million genetic 
markers [906,600 single nucleotide polymorphisms (SNPs) and 
more than 946,000 probes for the detection of copy number 
variation (CNVs)]. Several genomic regions, particularly those 
subjected to selection, were shown to display population-spe-
cific patterns of variation . 2  This led to a conceptual proposal 
that probing human genetic diversity in health research is 
essential (e.g., for pharmacogenetic studies of Africans). 
 Prof. Sarah Tishkoff (University of Pennsylvania, Philadel-
phia, PA ) spoke on “Genotype phenotype analysis of bitter 
taste perception of phenylthiocarbamide (PTC) in diverse 
African populations from Cameroon and Kenya.” She dis-
cussed the process of human adaptation, using, as an exam-
ple, the type II G protein coupled receptor ( TAS2R38 ) gene 
and PTC tasting.  TAS2R38 was examined in 25 Kenyan and 
20 Cameroonian populations, and the data showed a signifi-
cantly higher level of variation in Africans compared with 
other world populations as well as signatures of balancing 
selection or heterozygote advantage. This may indicate that 
bitter-taste perception is population specific, for reasons yet to 
be understood. 
 Prof. Himla Soodyall (University of the Witwatersrand, 
Witwatersrand, South Africa) presented “Y chromosome DNA 
variation in Khoe-San and Bantu speaking populations from 
South Africa.” She examined the patterns of genetic variation 
among Khoe-San in Namibia and South Africa to assess if there 
is a genetic basis to the linguistic differences of these popula-
tions. Her data showed that Khoe-San haplotypes are more simi-
lar to Northern Bantu groups. Prof. Soodyall further emphasized 
the need to share results from African studies to produce a more 
comprehensive picture of genetic variation and its implications. 
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 Dr. Rym Kefi Ben-Atig (Pasteur Institute, Tunis, Tunisia) 
introduced “Mitomedpop,” a DNA database that describes 
and documents mitochondrial DNA (mtDNA) variation. This 
work catalogues more than 3,000 mtDNA sequences collected 
from 25 populations from Southern Europe, 12 populations 
from North Africa, and 3 populations from the Near East. 
 Ms. Victoria Nembaware (University of Cape Town , Cape 
Town, South Africa) discussed a “Genome-wide survey of allele-
specific alternative splicing in humans.” Bioinformatic methods 
were used to identify 30,977 putative splicing polymorphisms, of 
which 1,085 were corroborated using public data on 166 lympho-
blastoid cell lines. The study provides an extensive resource that 
can be used to assess the possible effect on splicing of human 
polymorphisms located in putative splice-regulatory sites. 
 CANCER 
 The cancer session included talks that described research in 
Africans and populations of African descent, and as a group, 
they provided evidence that more research into genetic and 
environmental factors that contribute to cancers in Africa is 
urgently required. 
 Prof. Muntaser Ibrahim (University of Khartoum, Khartoum, 
Sudan) discussed the perception of the health burden of cancers 
in Sudan, with an emphasis on breast cancer and leukemia. This is 
reflected in the number of graduate students who choose to work 
on this topic (approximately 40% at the Institute of Endemic 
Diseases, Khartoum, Sudan). Several research approaches have 
been undertaken, including analysis of mutations, tumor-asso-
ciated methylation patterns, alterations in detoxifying pathway 
genes, causative viral infections, and mitochondrial mutations. 
 Prof. Franco M. Buonaguro (National Cancer Institute 
“Fondazione G. Pascale”, Naples, Italy) discussed the role of 
the polymorphism at codon 72 (Arg/Pro) of the  p53 gene in 
different cancer susceptibilities. His data documented a geo-
graphic gradient of this variant with lower frequency of the 
Arg allele in sub-Saharan populations (Uganda) relative to 
Caucasians (Italy). The data indicated no association of this 
variant with human papilloma virus (HPV)-related genital 
(cervical and penile) squamous cell cancers in either Uganda 
or Italy. In contrast, ultraviolet (UV) light-related squamous 
conjunctival cancer from Uganda was associated with HIV 
infection but not HPV. 
 Prof. Olufunmilayo Olopade’s (University of Chicago, 
Chicago, IL) presentation on “Early onset breast cancer in 
African American women” noted the lack of data on the preva-
lence and incidence of cancer across the African continent and the 
failure to address how genetics can help understand these condi-
tions at the population level. She advocated the case for genetic 
screening (e.g., in Nigeria where a limited number of  BRCA1 
mutations account for approximately 67% of breast cancers). 
 Dr. Bamidele Tayo (Loyola University, Maywood, IL) discussed 
data that showed the presence of both sporadic and Mendelian 
forms of ovarian cancer using the “Gilda Radner” Familial Ovarian 
Cancer Registry (based in the United States) that included more 
than 7,500 individuals. Study of a subgroup showed that  BRCA1/2 
mutations could be detected in 39% of the pedigrees. He also 
argued, based on his data, that mutations in other, as yet unidentified, 
genes may play a major role in susceptibility to ovarian cancer. 
 NON-COMMUNICABLE DISEASES 
 This session was preceded by a presentation entitled “How to 
fund your research” by Dr. Michael Chew of the Wellcome Trust 
(London, United Kingdom). Dr. Chew went through a detailed 
explanation of funding procedures and rationale adopted by the 
Trust to ensure that the best candidates from African institu-
tions are selected for training in programs developed in strong 
partnership with United Kingdom research centers. 
 The non-communicable diseases session included 10 talks 
that covered topics involving cardiovascular disease and hyper-
tension (Prof. Scott Williams, Vanderbilt University, Nashville, 
TN; Dr. Bamidele Tayo), diabetes and obesity (Dr. Sonia 
Abdelhak, Institut Pasteur, Tunis, Tunisia; Dr. Michele Ramsay, 
University of the Witwatersrand, Witwatersrand, South Africa; 
Dr. Ayo Doumatey, National Institutes of Health, Bethesda, 
MD), neurodegenerative diseases (Dr. G. Landoure, University 
of Bamako, Bamako, Mali); Dr. Sara Ibrahim, University of 
Gezira, Wad Madni, Sudan), and finally, some aspects of toxi-
cogenomics (Dr. Charles N. Fokunang, University of Yaoundé, 
Yaoundé, Cameroon). In addition, two additional talks discussed 
the role that admixture among populations can play in map-
ping disease genes (Prof. Charles Rotimi, National Institutes of 
Health, Bethesda, MD) and how genetic data can help eluci-
date health disparities in populations of the African diaspora 
(Prof. Georgia Dunstan, Howard University, Washington, DC). 
 Some highlights of this session include Dr. Tayo’s “Genetics 
of hypertension in Blacks: findings and prospects from stud-
ies among Nigerians,” which presented preliminary findings of 
the first genome-wide association study (GWAS) of hyperten-
sion in a sub-Saharan African cohort. Several interesting vari-
ants were discussed, but the point was made that such findings 
require a replication cohort; a request was made to AfSHG 
members and other attendees for collaboration on such a 
study by sharing DNA resources by forming a consortium 
among investigators with an interest in hypertension genetics. 
 Dr. Landoure discussed the topic “Neurogenetics in Mali: 
where are we?” This presentation emphasized the potential 
of genetic analyses in identifying factors that affect neurologi-
cal disease risk in an African context. Mutations were identi-
fied in 12 of 27 families studied with neurological diagnosis, 
and 7 of these families had novel mutations. This work showed 
the potential to not only replicate previously reported disease 
genes but also to identify new mutations that may be impor-
tant in elucidating etiology. 
 One important conclusion that could be taken from all of 
talks in this session is that although understanding infectious 
disease remains critically important to improving the health 
care of those in sub-Saharan Africa, non-communicable dis-
eases are becoming more prevalent; thus, they are increasingly 
significant from a public health perspective, and genetics has a 
central role to play in research on these diseases. 
 INFECTIOUS DISEASES 
 The infectious diseases session focused on the genetic sus-
ceptibility to bacterial ( Mycobacterium tuberculosis ), parasitic 
( Leishmania donovani ), and viral human immunodeficiency 
virus (HIV ) infections and was introduced by a main lec-
ture on “Cancer and infectious diseases” by Prof. Sir Walter 
Bodmer (Oxford University, Oxford, United Kingdom). 
 Prof. Bodmer took a historical perspective on the relationship 
between infection and cancer risk. He presented data indicat-
ing that nearly 20% of cancers worldwide are associated with 
a wide variety of infections, although several different mech-
anisms are involved in the oncogenic process. For example, 
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Epstein-Barr virus (EBV) and HPV, DNA viruses associated 
with Burkitt’s lymphoma and cervical carcinoma, respectively, 
have direct effects on carcinogenesis in ways analogous to 
oncogenic RNA retroviruses. Other pathogens [e.g., the hep-
atitis B virus (HBV) in liver cancer and  Helicobacter pylori 
in stomach cancer] probably act through inflammatory effects 
that can provide early stimulus to the outgrowth of a cancer. 
The role of HIV in cancers secondary to acquired immune 
deficiency syndrome (AIDS), such as Kaposi’s sarcoma, illus-
trates a third mechanism, namely the role of immune response 
to viruses such as HPV (e.g., in immunosuppressed kidney-
transplant recipients). Finally, Prof. Bodmer emphasized the 
relevance of cancer-prevention programs, including vaccina-
tion against HBV and HPV, particularly in Africa where infec-
tion-associated cancers are generally more prevalent than in 
developed nations. 
 Prof. William K. Scott (University of Miami, Miami, FL) ana-
lyzed the role of pro-inflammatory cytokine polymorphisms 
on susceptibility to pulmonary tuberculosis (PTB) in two West 
African populations (The Gambia and Guinea Bissau). Eight 
polymorphisms in the  IL-12B gene were examined in the two 
populations as well as a functional promoter variant in  MCP1 . 
The overall data provided evidence for the role of  IL-12B in 
PTB, confirmed that an  MCP1 promoter variant can influence 
host susceptibility, and suggested that an interaction between 
 IL-12B SNPs and the  MCP1 promoter variant affected dis-
ease risk. 
 Prof. Jennie Blackwell (University of Western Australia, 
Perth, Western Australia) presented a study on the genetic sus-
ceptibility to visceral leishmaniasis (VL). The study focused on 
Sudanese populations affected by an outbreak of VL caused 
by the protozoan parasite  Leishmania donovani . Families from 
several villages in eastern Sudan were studied using a linkage 
approach. Linkage to a previously reported locus on 22q12 
was not found. Instead, evidence was presented indicating a 
locus/loci at 1p22 and differences with particular Y chromo-
some lineages within each village. The results suggested strong 
lineage-specific VL-associated genes caused by founder effect 
and consanguinity in recent immigrant populations. 
 The last three presentations focused on HIV progression 
risk. Prof. Vittorio Colizzi (University of Rome “Tor Vergata,” 
Italy) described data on the association of human leucocyte 
antigens (HLA) alleles with progression to AIDS. In a pediat-
ric cohort from Libya, he showed long-term non-progression 
associated with the  HLA-B58 supertype. In contrast,  HLA-
B8 and  HLA-DR3 supertypes associated with progression 
to AIDS. Dr. Elias F. Onyoh (Cameroon Baptist Convention 
Health Board HIV/AIDS and Tuberculosis Control Programs, 
Cameroon) reported on a study that examined the role of 
chemokine ligand 3-like 1 ( CCL3L1 ) gene copy number with 
HIV-1 in a sample of Sudanese from Khartoum. These data 
led to the conclusion that copy number lower than the median 
per diploid genome was associated with increase of HIV-1 
infection in people exposed to the virus. Finally, Dr. Judith 
Torimiro (Center International de Référence “Chantal Biya” 
pour la Recherche sur la Prévention et la Prise en Charge 
du Virus de l’Immunodéficience Humaine [VIH]/Syndrome 
d’Immunodéficience Acquise [SIDA], Yaoundé, Cameroon ) 
presented data on the possible classification of protease and 
reverse transcriptase genes of HIV-1 isolates from Cameroon. 
The data clearly showed the need to assess specific HIV-1 
genotypic resistance to explain treatment failure and to choose 
appropriate antiretroviral drug strategies. 
 MEDICAL GENETICS 
 The session on Medical Genetics opened with a keynote pre-
sentation by Prof. Michael Hayden of the University of British 
Columbia, Vancouver, Canada. Prof. Hayden focused on the 
pharmacogenetics of severe adverse drug reactions that cause 
significant morbidity and mortality. Data were presented show-
ing how biomarkers have been identified for serious adverse 
drug reactions. The hope, as presented, is to extend work 
from the developed world to African populations where toxic 
effects may be more prevalent but are presently undetected. 
 Prof. Armand Bottani (Geneva Medical School, Geneva, 
Switzerland) provided an overview of clinical approaches to 
dysmorphology. He concluded, based on his extensive exper-
tise, that reaching a definitive diagnosis can be challenging and 
it requires systematic clinical evaluation, but it is essential to 
help advise families on outcomes and risks for future children. 
 The question of whether molecular cytogenetics can 
replace classical chromosomal analysis was addressed by 
Dr. Frederique Bena (Geneva University Hospital, Geneva, 
Switzerland). Among the techniques she discussed were com-
parative genomic hybridization (CGH). Dr. Bena gave exam-
ples of how array CGH has been used to detect genomic CNVs 
in patients with global developmental delay, mental retarda-
tion, autism, and multiple congenital anomalies. 
 The final speaker in this session was Dr. Ambroise Wonkam 
(local organizer of the meeting, University of Yaoundé, 
Yaoundé, Cameroon). Dr. Wonkam gave an overview of the 
practice of medical genetics in a resource-poor setting, using 
his own experience in Cameroon. He demonstrated that it 
is possible to develop such a clinical service, although chal-
lenges do exist. Dr. Wonkam also presented data showing that 
Cameroonian medical students and physicians accepted the 
principles of medical genetics for counseling, pre-natal diagno-
sis, and in some cases, medical abortion. Of particular interest, 
parents with a sickle cell anemia-affected child were interested 
in having pre-natal diagnosis, and the majority would opt for a 
medical abortion, if a fetus was found to be affected. 
 ETHNICITY, APPEARANCE, CULTURE, 
AND GENETICS 
 The final session of the meeting addressed a broad range of 
both longstanding and emerging ethical, legal, and social dimen-
sions of genetic and genomic research and practice in Africa. 
 Prof. Doris Schroeder (University of Central Lancashire, 
Preston, United Kingdom) discussed the concept sharing ben-
efits derived from research with indigenous populations. She 
pointed out that the Declaration of Helsinki requires that sci-
entists conducting research with indigenous populations show 
that the research is of benefit to the target community. She 
also suggested that decisions about benefit sharing be made 
before approval of studies and that communities be informed 
about the outcomes of studies in which they participate. The 
presentation concluded with a discussion of the potential ben-
efits and challenges of commercialization and patenting, and 
it emphasized the need for researchers to ensure mutually 
agreed to benefit, to give feedback, and to establish long-term 
transparent relationships with communities. 
 Dr. Ambroise Wonkam described the scope of medical 
genetics services in Cameroon, which primarily involves pre-
natal diagnosis for sickle cell disease (SCD). He drew attention 
to challenges such as limited knowledge of physicians about 
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genetics, shortage of financial, human, and technical resources for 
clinical genetics analyses and genetic counseling, and inadequate 
insurance coverage. Dr. Wonkam also discussed concerns regard-
ing authorship of local investigators on publications, informed 
consent, export and use of DNA samples, data sharing, capacity 
building, benefit and harm to participants and communities, and 
justice in relation to genetic and genomic studies conducted in 
Cameroon. He stressed the limitations in the number and capa-
bility of ethics committees to respond to these and other complex 
issues raised by molecular and medical genetics, and he called 
for increased efforts to address these limitations and improve the 
overall implementation and application of genetic and genomic 
research in Cameroon and sub-Saharan Africa as a whole. 
 Dr. Joshua Kimani (University of Nairobi, Nairobi, Kenya) 
raised a number of issues pertaining to the development of 
bio-repositories in Africa. He expressed concern that the exist-
ing weaknesses in regulatory frameworks needed to govern 
human subjects research in Africa, coupled with generally low 
literacy levels and high poverty rates, compromise the ability 
to deal with the growing interest in developing repositories 
with samples from Africa. Dr. Kimani highlighted questions 
about informed consent for present and future studies, recon-
tacting and reconsenting participants, maintenance of privacy 
and confidentiality, infrastructure for appropriate storage and 
use of samples, lack of any binding international law on bene-
fit sharing, vulnerability of African scientists, power dynamics 
among researchers and between researchers and participants, 
capacity building, ownership of and access to samples, and 
potential commercialization. He acknowledged that there are 
only a few bio-repositories in Africa but underscored the need 
to identify and address the current and potential challenges as 
the number of these resources increases. 
 Mr. Vence Bonham (National Institutes of Health, Bethesda, 
MD) addressed the application of concepts of culture and 
identity to international large-scale genomic studies. He stated 
that the primary goal of human genome research is to improve 
health, and he presented some principles for responsible large-
scale studies, including informed participation, respect of indi-
viduals’ genomes, and promotion of economic development. 
He talked about identity (ethnic, racial, and national) and cul-
ture and their interface with health. Focusing on the labeling 
of populations, he referred to the United States Census catego-
ries frequently used in research, the Indian Genome Variation 
Project that does not include population labels, and the PhenX 
project funded by the NHGRI to develop standard measures 
for collecting demographic and other types of information rel-
evant to GWAS. Mr. Bonham posed several questions for con-
sideration, answers to which could inform study designs and 
enhance the impact of genomic studies on global health. These 
include questions about how populations in large-scale stud-
ies should be defined and whether there should be interna-
tional guidelines for the collection and use of ethnic and racial 
categories in genomic and epidemiological studies. 
 The session ended with Prof. Michael Parker (Oxford 
University, Oxford, UK), who drew on his work with the Malaria 
Genomic Epidemiology Network (MalariaGEN) to discuss eth-
ical dimensions of collaborative global genomics research. He 
provided a brief introduction to the ethics support program in 
MalariaGEN, followed by some ethical points to consider when 
setting up a network involving both developed and developing 
country partners. Prof. Parker indicated that research funding for 
networks has increased and that new ethical issues have arisen, 
largely because of genomics. He discussed challenges including 
the value, validity, and process of consent. He also talked about 
the engagement of communities in research, focusing on ques-
tions such as: who and what is the community? What engagement 
methods are appropriate and successful? Who can approve the 
use of sample collections? What do consent forms say about data 
release and data sharing? What are the ethical implications of 
not using collected samples? What are the concerns and implica-
tions regarding the shipment of samples? Prof. Parker revisited 
the discussion of benefit sharing—how we think about benefits 
and who are the beneficiaries. He ended his presentation with a 
look at the social value of health-related research and its critical 
role in guiding the actions of the various stakeholders. 
 The winners of the Young Investigator Prize 2009 were 
Dr. Rym Kefi-Ben Atig (Institut Pasteur de Tunis, Tunisia), 
Dr. Digna Velez (University of Miami, Miami, FL), Dr. Elias 
F. Onyoh (CBCHB HIV/AIDS and TB Control Programs, 
Cameroon), and Ms. Victoria Nembaware (University of Cape 
Town, Cape Town, South Africa). 
 The meeting was closed by a debate on how to link up to or 
create web resources to access data generated from African 
studies and ethical issues around consent for sharing datasets 
that will require thorough consideration. 
 The next conference will be held in Cape Town, South 
Africa, on March 6–9, 2011 (see announcement on  www.afshg
.org and  www.humangenetics2011.org ). 
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